Adding infliximab to standard intravenous immunoglobulin to reduce inflammation in acute Kawasaki disease is safe in children, even those younger than 1 year, according to a phase 3 randomized trial presented at IDWeek 2012.
Your search for hypertension returned 2532 results
The FDA has approved Barhemsys (amisulpride; Acacia Pharma) for the prevention of postoperative nausea and vomiting (PONV), either alone or in combination with an antiemetic of a different class and for the treatment of PONV in patients who have received antiemetic prophylaxis with an agent of a different class or have not received prophylaxis.
The approval was based on data from the phase 1/2 ZUMA-3 trial which evaluated Tecartus in 71 adults with relapsed or refractory B-cell precursor ALL.
Mr. C, a 30-year-old male with Crohn’s disease, presented to his clinician with symptoms of fatigue, lethargy, headaches, pallor, hair loss, irritability, and weakness.
The approval was based on data from the phase 2 IMCgp100-202 trial that assessed Kimmtrak in 378 HLA-A*02:01-positive adults with previously untreated metastatic uveal melanoma.
At a median follow-up of 12 weeks, results showed that the composite response rate was 23%.
Low back pain is one of the top 10 most common reasons for doctor office visits in the United States; approximately 80% of adults seek care at some time for acute low back pain. The differential diagnosis for low back pain and the importance of identifying clinical red and yellow flags during evaluation was presented at the 29th Annual Scientific Meeting of the American Pain Society.
By clarifying the risk for anaphylaxis, study findings can contribute to the choice of IV iron preparations, according to investigators.
FDA-approved therapies for the management of Clostridioides difficile infection (CDI) in adults.
The approval was based on data from the phase 3 ULTIMATE 1 and ULTIMATE 2 trials that compared ublituximab-xiiy to teriflunomide in patients with relapsing multiple sclerosis.